Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer

Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy

(2019) Imran Siddiqui et al.   IMMUNITY

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System

(2019) Shweta Joshi et al.   Journal of Oncology

Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer

(2019) Christopher J. Halbrook et al.   Cell Metabolism

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy

(2018) Junjie Wu et al.   CANCER LETTERS

Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer

(2018) Tamara Muliaditan et al.   CLINICAL CANCER RESEARCH

The impact of the intestinal microbiota in therapeutic responses against cancer

(2018) Anne-Gaëlle Goubet et al.   COMPTES RENDUS BIOLOGIES

Docetaxel promotes the generation of anti-tumorigenic human macrophages

(2018) Camilla Rydberg Millrud et al.   EXPERIMENTAL CELL RESEARCH

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

(2018) Jinyang Li et al.   IMMUNITY

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

(2018) Franck Pagès et al.   LANCET

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression

(2018) Viktor Fleming et al.   Frontiers in Immunology

Chemotherapy Combines Effectively with Anti–PD-L1 Treatment and Can Augment Antitumor Responses

(2018) Rafael Cubas et al.   JOURNAL OF IMMUNOLOGY

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

(2018) David R. Gandara et al.   NATURE MEDICINE

Pembrolizumab plus Chemotherapy in Lung Cancer

(2018)   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

(2018) Yiyi Yan et al.   Frontiers in Immunology

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer

(2018) Fanny Ledys et al.   Journal for ImmunoTherapy of Cancer

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer

(2017) Jane Cullis et al.   Cancer Immunology Research

Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance

(2017) Alessandra Zingoni et al.   Frontiers in Immunology

Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)

(2016) J. M. Kim et al.   ANNALS OF ONCOLOGY

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade

(2016) Haidong Tang et al.   CANCER CELL

Mutational Landscape and Sensitivity to Immune Checkpoint Blockers

(2016) R. M. Chabanon et al.   CLINICAL CANCER RESEARCH

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

(2016) Christina Pfirschke et al.   IMMUNITY

Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells

(2016) Tze-Sian Chan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

(2016) John K. Chan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy

(2016) Kazuhide Sato et al.   Science Translational Medicine

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

(2015) J. Peng et al.   CANCER RESEARCH

Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6

(2015) Guoshuai Cao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Immune-mediated mechanisms influencing the efficacy of anticancer therapies

(2015) Seth B. Coffelt et al.   TRENDS IN IMMUNOLOGY

Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints

(2015) M. E. Mikucki et al.   Nature Communications

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

(2015) Leisha A. Emens et al.   Cancer Immunology Research

Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells

(2014) Brian Ruffell et al.   CANCER CELL

IL-17A Produced by    T Cells Promotes Tumor Growth in Hepatocellular Carcinoma

(2014) S. Ma et al.   CANCER RESEARCH

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response

(2014) Julia M. Houthuijzen et al.   Nature Communications

Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer

(2013) D. Alizadeh et al.   CANCER RESEARCH

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

(2013) L Bracci et al.   CELL DEATH AND DIFFERENTIATION

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death

(2013) James W. Hodge et al.   INTERNATIONAL JOURNAL OF CANCER

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

(2013) Laura Ridolfi et al.   Journal of Translational Medicine

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Combination of a Low-Dose Chemotherapeutic Agent, 5-Fluorouracil, and an Adenoviral Tumor Vaccine Has a Synergistic Benefit on Survival in a Tumor Model System

(2013) Sean M. Geary et al.   PLoS One

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

(2013) S. Viaud et al.   SCIENCE

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Dose-Dense Chemotherapy Improves Mechanisms of Antitumor Immune Response

(2012) C.-L. Chang et al.   CANCER RESEARCH

A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death

(2012) Abhishek D Garg et al.   EMBO JOURNAL

Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cellsin vitroin a TLR4-independent manner

(2012) Tillmann Michels et al.   Journal of Immunotoxicology

Inflammasomes in carcinogenesis and anticancer immune responses

(2012) Laurence Zitvogel et al.   NATURE IMMUNOLOGY

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

(2012) Mélanie Bruchard et al.   NATURE MEDICINE

Mesenchymal Stem Cells Induce Resistance to Chemotherapy through the Release of Platinum-Induced Fatty Acids

(2011) Jeanine M.L. Roodhart et al.   CANCER CELL

Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors

(2011) S. R. Mattarollo et al.   CANCER RESEARCH

Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control

(2011) M. Hong et al.   CANCER RESEARCH

Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide

(2011) F. Moschella et al.   CANCER RESEARCH

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer

(2011) T. Shree et al.   GENES & DEVELOPMENT

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis

(2011) Wei-Ting Hwang et al.   GYNECOLOGIC ONCOLOGY

Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy

(2011) Yuting Ma et al.   JOURNAL OF EXPERIMENTAL MEDICINE

DNA Alkylating Therapy Induces Tumor Regression through an HMGB1-Mediated Activation of Innate Immunity

(2011) J. L. Guerriero et al.   JOURNAL OF IMMUNOLOGY

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

(2011) Sylvain Ladoire et al.   JOURNAL OF PATHOLOGY

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

(2011) M. Michaud et al.   SCIENCE

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

(2011) David G. DeNardo et al.   Cancer Discovery

Combination strategies for enhancing the efficacy of immunotherapy in cancer patients

(2010) Federica Moschella et al.   Annals of the New York Academy of Sciences

Mechanisms of Cell Protection by Heme Oxygenase-1

(2010) Raffaella Gozzelino et al.   Annual Review of Pharmacology and Toxicology

Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis

(2010) G. Schiavoni et al.   CANCER RESEARCH

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity

(2010) J. Vincent et al.   CANCER RESEARCH

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

(2010) K. N. Kodumudi et al.   CLINICAL CANCER RESEARCH

Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor

(2010) Ilaria Marigo et al.   IMMUNITY

Endogenous toll-like receptor ligands and their biological significance

(2010) Li Yu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer

(2010) Katsuhiko Shimizu et al.   Journal of Thoracic Oncology

Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein- 

(2010) M. Kraman et al.   SCIENCE

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

(2009) W M Liu et al.   BRITISH JOURNAL OF CANCER

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

(2009) Isabelle Ray-Coquard et al.   CANCER RESEARCH

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death

(2009) Theocharis Panaretakis et al.   EMBO JOURNAL

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

(2009) Noriyuki Katsumata et al.   LANCET

Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance

(2009) Michael R. Elliott et al.   NATURE

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

(2009) François Ghiringhelli et al.   NATURE MEDICINE

The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death

(2008) T Panaretakis et al.   CELL DEATH AND DIFFERENTIATION

Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy

(2008) Lei Zhang et al.   CLINICAL IMMUNOLOGY

Paclitaxel Binding to Human and Murine MD-2

(2008) Shanta M. Zimmer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY